Aras Azadian

Title
Chief Executive Officer
@
Company
Avicanna

Utilizing his extensive senior management experience in both financial and bio-technology sectors, Aras co-founded Avicanna with the vision of establishing a bio-pharmaceutical company with a strict focus on medical and pharmaceutical applications of cannabinoids. His expertise and experience in the biotechnology industry have been integral to Avicanna’s thought leadership pertaining to R&D and clinical development. Since 2016 Aras has successfully led a team of executives, scientists, and medical professionals across several countries with the vision of vertical integration and a strong company focus on quality controls, scientific vigour and competitive advantages. Aras holds a Bachelor of Economics degree from York University and an International master’s in management degree from EADA Business School in Barcelona, Spain.

Upcoming Speaking Events

  • Cannabinoid-based medicines in the Fight Against Epilepsy
    hosted by Avicanna
    December 6, 2022
    11:00 AM - 12:00 PM
    Webcast

Past Speaking Events

  • DISRUPTING THE GLOBAL PHARMACEUTICAL INDUSTRY WITH CANNABINOID-BASED MEDICINE
    hosted by Avicanna
    July 14, 2022
    12:30 PM - 1:00 PM
    Keynote
  • How 1 Interview Changed the NBA Players Association's Medical Cannabis Policy, Enabling Better Recovery for Athletes
    hosted by Avicanna
    August 4, 2022
    1:00 PM - 2:00 PM
    Panel

About Avicanna

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.

Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.